Resources
Two thirds of launches miss forecast.
The causes are commercial rather than clinical, and they are set long before approval.
Two thirds of drug launches miss their first year sales forecast, and the causes are commercial rather than clinical. Companies that combine clinical differentiation with manufacturing commitment achieve 67 percent overperformance against 49 percent for differentiation alone, and the successful group starts commercial work more than 30 months before approval rather than 12. This collection covers launch forecasting, patient access modeling, and the 2030 patent cliff.
That architecture is not exciting. It is ontology layers, governance scaffolding, MLR workflow design, audit trails, and human in the loop accountability. Boring infrastructure that does not photograph well in an annual report. Foundational work that makes the difference between an AI deployment that ships and one that quietly stalls in pilot for the third year running.
This collection covers why two thirds of drug launches miss forecast and what the other third do differently. Launch forecasting that accounts for patient access rather than eligibility, the timing decisions made 30 months out that determine the outcome, and how the 2030 patent cliff reshapes the calculus. Written for the people who own the number.
Key Insights
What the writing is showing.
Two thirds of drug launches miss first year sales forecasts. Only one in ten launches between 2020 and 2024 cleared 100 million dollars in year one.
Companies starting commercial work 30 plus months before approval reach 67 percent overperformance. Those starting at 12 months reach 49 percent.
Roughly 400 billion dollars of branded pharma revenue is exposed to the 2030 patent cliff.
Read Deeper
Articles in this collection.
Pharma
23 Obesity Drugs Are Coming By 2031. Your Field Force Can Cover One. Here Is The Math.
23 new obesity drugs are projected to launch by 2031. The average pharma field force can scale to cover maybe one. Here is how pharma actually wins the GLP-1 decade.
Jun 22 · 3 min read
AI
Pharma Reps Forget Most of Launch Training Within 30 Days. Here Is the L&D System That Fixes It.
Pharma reps forget up to 80% of launch training within 30 days. Here is the spaced-repetition L&D system that fixes it, and what a 30-day pilot looks like in your org.
Jun 12 · 3 min read
Pharma, Business
The 2030 Patent Cliff: $400 Billion in Branded Pharma Revenue at Risk
Between 2025 and 2030, somewhere between 200 and 400 billion dollars in branded pharmaceutical revenue will lose patent protection. Keytruda, Stelara, Eliquis, Eylea, Ozempic by 2032.
May 22 · 3 min read
Pharma, Business
Lilly Hit $1 Trillion. What That Means for the Next Decade of Pharma
On November 21, 2025, Eli Lilly became the first pharmaceutical company in history to cross a one trillion dollar market capitalization. The lesson is what pharma boards must internalize about the next decade of value
May 21 · 3 min read
Pharma, Business
The Patient Your Pharma Forecast Forgot
Pharma forecasts are built in three stages by three different teams. The third arrives too late to change anything. Here is why and what to fix.
Apr 15 · 3 min read
Pharma, Business
Why 66% of Drug Launches Miss Their Forecast in 2026
Two thirds of pharma drug launches miss first year sales targets. The real reason is not the molecule. It is the commercial system around it.
Mar 25 · 3 min read
Questions
What people ask about pharma launches.
Want to talk about how this applies to your organization?
30 minute call. No deck. We will figure out if I can help.